Crossmark

Drug delivery of 6-bromoindirubin-3’-glycerol-oxime ether employing poly(d,l-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents

Crossref DOI link: https://doi.org/10.1186/s12951-021-01179-7

Published Online: 2022-01-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Czapka, Anna http://orcid.org/0000-0002-6849-7020
Grune, Christian

Schädel, Patrick http://orcid.org/0000-0002-9586-6653
Bachmann, Vivien

Scheuer, Karl

Dirauf, Michael

Weber, Christine

Skaltsounis, Alexios-Leandros

Jandt, Klaus D.

Schubert, Ulrich S.

Fischer, Dagmar

Werz, Oliver http://orcid.org/0000-0002-5064-4379
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (SFB 1278, SFB 1127, INST 275/389-1 FUGG, AOBJ:640980)

Friedrich-Schiller-Universität Jena
License Information

Text and Data Mining valid from 2022-01-04

Version of Record valid from 2022-01-04
More Information

Article History

Received: 30 September 2021

Accepted: 2 December 2021

First Online: 4 January 2022

Declarations

:

: The experimental protocol for blood isolation and whole blood experiments were approved by the ethical committee of the University Hospital Jena (approval no. 5050–01/17). All methods were performed in accordance with the relevant guidelines and regulations.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below